Antipodes Partners LTD Day One Biopharmaceuticals, Inc. Transaction History
Antipodes Partners LTD
- $4.06 Billion
- Q3 2025
A detailed history of Antipodes Partners LTD transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 1,731 shares of DAWN stock, worth $15,232. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,731
Previous 3,006
42.42%
Holding current value
$15,232
Previous $19,000
36.84%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding DAWN
# of Institutions
178Shares Held
70.5MCall Options Held
42.8KPut Options Held
60.3K-
Atlas Venture Life Science Advisors, LLC6.43MShares$56.6 Million10.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.18MShares$54.4 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY4.71MShares$41.4 Million0.62% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$39.9 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA3.48MShares$30.6 Million0.01% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $646M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...